Author: admin

DelveInsight’s “Chronic Plaque Psoriasis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Chronic Plaque Psoriasis, historical and forecasted epidemiology as well as the Chronic Plaque Psoriasis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Chronic Plaque Psoriasis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Chronic Plaque Psoriasis Market Forecast

Some of the key facts of the Chronic Plaque Psoriasis Market Report:

• The Chronic Plaque Psoriasis market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

• In February 2025, Vyne Therapeutics initiated a randomized Phase Ib clinical trial by dosing the first participant with VYN202, an oral therapy for moderate-to-severe plaque psoriasis. This double-blind, placebo-controlled study includes three dosing groups to evaluate the treatment’s safety, pharmacokinetics, and tolerability. Participants will receive either 0.25mg, 0.5mg, or 1mg doses of VYN202, or a placebo, administered once daily over a 12-week period.

• In December 2024, Bristol Myers Squibb (NYSE: BMY) announced findings from the POETYK PsA-1 (IM011-054) and POETYK PsA-2 (IM011-055) Phase 3 trials assessing the efficacy and safety of Sotyktu (deucravacitinib) in adults with active psoriatic arthritis (PsA). Both studies achieved their primary endpoint, demonstrating a significantly higher percentage of Sotyktu-treated patients attaining an ACR20 response—indicating at least a 20% improvement in disease signs and symptoms—after 16 weeks of treatment compared to placebo.

• In 2023, the market size for chronic plaque psoriasis in the United States was around USD 14 billion. It is projected to expand at a CAGR of 2.8% throughout the forecast period (2024-2034).

• In the 7MM, the US had the highest number of prevalent chronic plaque psoriasis cases in 2023, with approximately 6.4 million cases. These figures are anticipated to rise throughout the forecast period.

• In 2023, nearly 80% of chronic plaque psoriasis cases were classified as mild.

• In 2023, the United States recorded approximately 6,425,000 diagnosed prevalent instances of plaque psoriasis. Forecasts indicate a rise in these cases during the projected period from 2024 to 2034.

• As stated by the National Psoriasis Foundation, psoriasis affects roughly 125 million individuals globally, with approximately 14 million cases in Europe and over 8 million in the United States alone. Among these patients, around 80-90% are afflicted with plaque psoriasis.

• In September 2023, Takeda has revealed encouraging top-line findings from its Phase IIb trial, which was a randomized, double-blind, and placebo-controlled study assessing TAK-279. TAK-279 is an experimental oral allosteric tyrosine kinase 2 (TYK2) inhibitor featuring enhanced selectivity in individuals experiencing active psoriatic arthritis.

• According to the National Psoriasis Foundation, plaque psoriasis, the most prevalent type of psoriasis, manifests as elevated, reddened patches coated with a whitish accumulation of dead skin cells. Roughly 20% of individuals with psoriasis experience moderate to severe cases of plaque psoriasis.

• According to the Centers for Disease Control and Prevention (2020), Psoriasis stands as the predominant inflammatory condition in the United States, impacting around 7.4 million American adults.

• Chronic Plaque Psoriasis, the most prevalent type of psoriasis, affects approximately 90% of individuals with the condition. Among those affected, around 20% to 30% experience moderate to severe symptoms.

• Key Chronic Plaque Psoriasis Companies: Zai Lab, UCB Biopharma SRL, Taizhou Mabtech Pharmaceutical, Sun Pharma, Janssen Research & Development, Livzon Pharmaceutical, Alza Corporation, DE, USA, Momenta Pharmaceuticals, Almirall, S.A., UCB Biopharma SRL, Arcutis Biotherapeutics, Pfizer, Arcutis Biotherapeutics, Inc., Coherus Biosciences, Inc., Samsung Bioepis Co., Ltd., Alvotech Swiss AG, Mitsubishi Tanabe Pharma, ApoPharma, Cellceutix Corporation, Kadmon Corporation, LLC, Novartis, Coherus Biosciences, AbbVie, Astellas Pharma, Galderma R&D, UCB Biopharma SRL, and others

• Key Chronic Plaque Psoriasis Therapies: ZL-1102, Certolizumab pegol, CMAB015, Tildrakizumab, Guselkumab, LZM012, RWJ-445380, M923, LAS41008, Bimekizumab, Topical roflumilast, PF-06700841, ARQ-151 0.3% cream, CHS-1420, Humira (Adalimumab), Adalimumab, MT-1303, Apo805K1, Prurisol, Belumosudil, Secukinumab, Etanercept, Adalimumab, alefacept, Calcitriol 3mcg/g, Certolizumab pegol, and others

• The Chronic Plaque Psoriasis epidemiology based on gender analyzed that males are more affected by Chronic Plaque Psoriasis than females

• The Chronic Plaque Psoriasis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chronic Plaque Psoriasis pipeline products will significantly revolutionize the Chronic Plaque Psoriasis market dynamics.

Get a Free sample for the Chronic Plaque Psoriasis Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/chronic-plaque-psoriasis-market

Chronic Plaque Psoriasis Overview

Chronic plaque psoriasis is the most common form of psoriasis, a chronic autoimmune skin disorder characterized by red, raised, and scaly patches known as plaques. These plaques typically appear on the scalp, knees, elbows, lower back, and other areas of the body. Chronic plaque psoriasis tends to persist over time, with periods of exacerbation and remission.

Chronic Plaque Psoriasis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Chronic Plaque Psoriasis Epidemiology Segmentation:

The Chronic Plaque Psoriasis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Chronic Plaque Psoriasis

• Prevalent Cases of Chronic Plaque Psoriasis by severity

• Gender-specific Prevalence of Chronic Plaque Psoriasis

• Diagnosed Cases of Episodic and Chronic Chronic Plaque Psoriasis

Download the report to understand which factors are driving Chronic Plaque Psoriasis epidemiology trends @ Chronic Plaque Psoriasis Epidemiology Forecast

Chronic Plaque Psoriasis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chronic Plaque Psoriasis market or expected to get launched during the study period. The analysis covers Chronic Plaque Psoriasis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Chronic Plaque Psoriasis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Chronic Plaque Psoriasis Therapies and Key Companies

• ZL-1102: Zai Lab

• Certolizumab pegol: UCB Biopharma SRL

• CMAB015: Taizhou Mabtech Pharmaceutical

• Tildrakizumab: Sun Pharma

• Guselkumab: Janssen Research & Development

• LZM012: Livzon Pharmaceutical

• RWJ-445380: Alza Corporation, DE, USA

• M923: Momenta Pharmaceuticals

• LAS41008: Almirall, S.A.

• Bimekizumab: UCB Biopharma SRL

• Topical roflumilast: Arcutis Biotherapeutics

• PF-06700841: Pfizer

• ARQ-151 0.3% cream: Arcutis Biotherapeutics, Inc.

• CHS-1420: Coherus Biosciences, Inc.

• Humira (Adalimumab): Samsung Bioepis Co., Ltd.

• Adalimumab: Alvotech Swiss AG

• MT-1303: Mitsubishi Tanabe Pharma

• Apo805K1: ApoPharma

• Prurisol: Cellceutix Corporation

• Belumosudil: Kadmon Corporation, LLC

• Secukinumab: Novartis

• Etanercept: Coherus Biosciences

• Adalimumab: AbbVie

• alefacept: Astellas Pharma

• Calcitriol 3mcg/g: Galderma R&D

• Certolizumab pegol: UCB Biopharma SRL

Discover more about therapies set to grab major Chronic Plaque Psoriasis market share @ Chronic Plaque Psoriasis Treatment Landscape

Chronic Plaque Psoriasis Market Strengths

• An enriched investment in spreading disease awareness, direct to consumer advertisement and other private/government initiatives would increase proposinity of opting treatment and compliance, hence the market will grow in our forecast period.

• The Increasingly prevalent pool of psoriasis could be seen as expansion of the potential market thus making it an attractive therapy area to invest in.

Chronic Plaque Psoriasis Market Opportunities

• Patients with Chronic Plaque Psoriasis confront significant challenges due to lack of curative therapeutic choices.

• Anti-TNF agents are believed to be one of the most effective medication type, however, usage of these drugs is associated with the development of immunogenicity and significant side effects.

Scope of the Chronic Plaque Psoriasis Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Chronic Plaque Psoriasis Companies: Zai Lab, UCB Biopharma SRL, Taizhou Mabtech Pharmaceutical, Sun Pharma, Janssen Research & Development, Livzon Pharmaceutical, Alza Corporation, DE, USA, Momenta Pharmaceuticals, Almirall, S.A., UCB Biopharma SRL, Arcutis Biotherapeutics, Pfizer, Arcutis Biotherapeutics, Inc., Coherus Biosciences, Inc., Samsung Bioepis Co., Ltd., Alvotech Swiss AG, Mitsubishi Tanabe Pharma, ApoPharma, Cellceutix Corporation, Kadmon Corporation, LLC, Novartis, Coherus Biosciences, AbbVie, Astellas Pharma, Galderma R&D, UCB Biopharma SRL, and others

• Key Chronic Plaque Psoriasis Therapies: ZL-1102, Certolizumab pegol, CMAB015, Tildrakizumab, Guselkumab, LZM012, RWJ-445380, M923, LAS41008, Bimekizumab, Topical roflumilast, PF-06700841, ARQ-151 0.3% cream, CHS-1420, Humira (Adalimumab), Adalimumab, MT-1303, Apo805K1, Prurisol, Belumosudil, Secukinumab, Etanercept, Adalimumab, alefacept, Calcitriol 3mcg/g, Certolizumab pegol, and others

• Chronic Plaque Psoriasis Therapeutic Assessment: Chronic Plaque Psoriasis current marketed and Chronic Plaque Psoriasis emerging therapies

• Chronic Plaque Psoriasis Market Dynamics: Chronic Plaque Psoriasis market drivers and Chronic Plaque Psoriasis market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Chronic Plaque Psoriasis Unmet Needs, KOL’s views, Analyst’s views, Chronic Plaque Psoriasis Market Access and Reimbursement

To know more about Chronic Plaque Psoriasis companies working in the treatment market, visit @ Chronic Plaque Psoriasis Clinical Trials and Therapeutic Assessment

Table of Contents

1. Chronic Plaque Psoriasis Market Report Introduction

2. Executive Summary for Chronic Plaque Psoriasis

3. SWOT analysis of Chronic Plaque Psoriasis

4. Chronic Plaque Psoriasis Patient Share (%) Overview at a Glance

5. Chronic Plaque Psoriasis Market Overview at a Glance

6. Chronic Plaque Psoriasis Disease Background and Overview

7. Chronic Plaque Psoriasis Epidemiology and Patient Population

8. Country-Specific Patient Population of Chronic Plaque Psoriasis

9. Chronic Plaque Psoriasis Current Treatment and Medical Practices

10. Chronic Plaque Psoriasis Unmet Needs

11. Chronic Plaque Psoriasis Emerging Therapies

12. Chronic Plaque Psoriasis Market Outlook

13. Country-Wise Chronic Plaque Psoriasis Market Analysis (2020–2034)

14. Chronic Plaque Psoriasis Market Access and Reimbursement of Therapies

15. Chronic Plaque Psoriasis Market Drivers

16. Chronic Plaque Psoriasis Market Barriers

17. Chronic Plaque Psoriasis Appendix

18. Chronic Plaque Psoriasis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Chronic Plaque Psoriasis Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Zai Lab, UCB Biopharma SRL, Taizhou Mabtech Pharma, Sun Pharma, Janssen R&D, Livzon Pharma

DelveInsight’s “Ichthyosis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Ichthyosis, historical and forecasted epidemiology as well as the Ichthyosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Ichthyosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Ichthyosis Market Forecast

Some of the key facts of the Ichthyosis Market Report:

• The Ichthyosis market size is anticipated to grow with a significant CAGR during the study period (2019-2032)

• In January 2025, Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX), a clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, has reported additional positive interim data from its ongoing clinical study for Netherton Syndrome. The company previously shared promising results from the first subject dosed twice daily with QRX003 at the six-week midpoint. Now, Quoin has released clinical data following the full 12-week treatment period, highlighting significant improvements across all measured clinical endpoints. The observed results further support the potential efficacy of QRX003 in treating Netherton Syndrome, reinforcing its role as a promising therapeutic candidate for this rare condition.

• In August 2024, Timber Pharmaceuticals Inc., a LEO Pharma company, has released findings from the randomized, double-blind 12-week phase of the ASCEND trial. The study did not demonstrate a statistically significant difference in response rates between patients treated with TMB-001 and those receiving the vehicle after 12 weeks. ASCEND is a Phase 3 clinical trial evaluating TMB-001, an investigational topical isotretinoin formulation, as a potential treatment for moderate to severe congenital ichthyosis.

• In March 2024, Timber Pharmaceuticals, Inc., a subsidiary of LEO Pharma, presented preliminary findings from the ASCEND trial during a late-breaking session at the 2024 American Academy of Dermatology (AAD) Annual Meeting. The ASCEND trial evaluates TMB-001, an investigational polyethylene glycol (iPEG™)-based topical isotretinoin, being developed to treat moderate-to-severe X-linked and autosomal recessive congenital ichthyosis (CI). CI is a group of rare genetic keratinization disorders characterized by dry, thickened, and scaling skin. Currently, no FDA-approved treatments are available specifically for CI.

• Ichthyosis affects approximately 1 in 250,000 births for the most severe forms, while milder forms like Ichthyosis vulgaris occur in about 1 in 250 to 1 in 1,000 people.

• There are more than 20 different types of ichthyosis, including Ichthyosis vulgaris, X-linked ichthyosis, and Harlequin ichthyosis.

• Most types are inherited in an autosomal dominant or recessive manner, while some can be acquired due to underlying conditions.

• X-linked ichthyosis primarily affects males, while other forms occur in both genders.

• Key Ichthyosis Companies: Timber Pharmaceuticals, Krystal Biotech, GSK, Timber Pharmcecuticals, Janssen Scientific, Patagonia Pharma, Crown Laboratories, Inc, and others

• Key Ichthyosis Therapies: TMB-001, KB105, Liarozole, TMB-001, Ustekinumab, PAT-001, Isotretinoin, 146-9251, and others

• The Ichthyosis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Ichthyosis pipeline products will significantly revolutionize the Ichthyosis market dynamics.

Ichthyosis Overview

Ichthyosis is a group of rare genetic skin disorders characterized by dry, scaly, thickened, or flaky skin due to abnormal skin cell shedding and renewal. It results from mutations affecting skin barrier function, leading to excessive keratin buildup. Symptoms can range from mild dryness to severe scaling and cracking, often causing discomfort and an increased risk of infections. The condition may be present at birth or develop later in life. While there is no cure, treatment focuses on managing symptoms through moisturizing creams, keratolytic agents, and, in some cases, systemic therapies to improve skin hydration and reduce scaling.

Get a Free sample for the Ichthyosis Market Report

https://www.delveinsight.com/report-store/ichthyosis-market

Ichthyosis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Ichthyosis Epidemiology Segmentation:

The Ichthyosis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Ichthyosis

• Prevalent Cases of Ichthyosis by severity

• Gender-specific Prevalence of Ichthyosis

• Diagnosed Cases of Episodic and Chronic Ichthyosis

Download the report to understand which factors are driving Ichthyosis epidemiology trends @ Ichthyosis Epidemiology Forecast

Ichthyosis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Ichthyosis market or expected to get launched during the study period. The analysis covers Ichthyosis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Ichthyosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Ichthyosis Therapies and Key Companies

• TMB-001: Timber Pharmaceuticals

• KB105: Krystal Biotech

• Liarozole: GSK

• TMB-001: Timber Pharmcecuticals

• Ustekinumab: Janssen Scientific

• PAT-001: Patagonia Pharma

• Isotretinoin: Timber Pharmcuticals

• 146-9251: Crown Laboratories, Inc

Discover more about therapies set to grab major Ichthyosis market share @ Ichthyosis Treatment Market

Ichthyosis Market Strengths

• Ongoing Search for Cure – Along with clinical trials in Ichthyosis, various institute/ organization/ and groups are conducting research to find cure for this disease.

• Various Organization and Foundation Support – Organizations and government level support has aided in further development of angleman syndrome treatment

Ichthyosis Market Opportunities

• Lack of treatment protocols

• Research funding

• Biomarker research

• Integrative and novel therapies

Scope of the Ichthyosis Market Report

• Study Period: 2019–2032

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Ichthyosis Companies: Timber Pharmaceuticals, Krystal Biotech, GSK, Timber Pharmcecuticals, Janssen Scientific, Patagonia Pharma, Crown Laboratories, Inc, and others

• Key Ichthyosis Therapies: TMB-001, KB105, Liarozole, TMB-001, Ustekinumab, PAT-001, Isotretinoin, 146-9251, and others

• Ichthyosis Therapeutic Assessment: Ichthyosis current marketed and Ichthyosis emerging therapies

• Ichthyosis Market Dynamics: Ichthyosis market drivers and Ichthyosis market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Ichthyosis Unmet Needs, KOL’s views, Analyst’s views, Ichthyosis Market Access and Reimbursement

To know more about Ichthyosis companies working in the treatment market, visit @ Ichthyosis Clinical Trials and Therapeutic Assessment

Table of Contents

1. Ichthyosis Market Report Introduction

2. Executive Summary for Ichthyosis

3. SWOT analysis of Ichthyosis

4. Ichthyosis Patient Share (%) Overview at a Glance

5. Ichthyosis Market Overview at a Glance

6. Ichthyosis Disease Background and Overview

7. Ichthyosis Epidemiology and Patient Population

8. Country-Specific Patient Population of Ichthyosis

9. Ichthyosis Current Treatment and Medical Practices

10. Ichthyosis Unmet Needs

11. Ichthyosis Emerging Therapies

12. Ichthyosis Market Outlook

13. Country-Wise Ichthyosis Market Analysis (2019–2032)

14. Ichthyosis Market Access and Reimbursement of Therapies

15. Ichthyosis Market Drivers

16. Ichthyosis Market Barriers

17. Ichthyosis Appendix

18. Ichthyosis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Ichthyosis Market Expected to Experience Major Growth by 2032, According to DelveInsight | Timber Pharma, Krystal Biotech, GSK, Timber Pharma, Janssen Scientific

The 7MM Graft Versus Host Disease (GvHD) market has demonstrated substantial growth in recent years, fueled by rising transplant rates, an aging population, and the introduction of innovative therapies such as ZEMAIRA, EQ001, MaaT013, and RGI-2001, among others. According to DelveInsight’s comprehensive analysis, key pharmaceutical companies including ICSL Behring, Equillium, Biocon, MaaT Pharma, REGiMMUNE, ReAlta Life Sciences, Ono Pharmaceutical (Deciphera Pharmaceuticals), Medsenic, BioSenic, ASC Therapeutics, Cynata Therapeutics, Evive Biotech (Yifan Pharmaceutical), Ironwood, Medac, and others leading innovation in this space.

DelveInsight’s “Graft Versus Host Disease Market Insights, Epidemiology, and Market Forecast – 2034” report provides an in-depth understanding of Graft Versus Host Disease (GvHD), historical and forecasted epidemiology, as well as the Graft Versus Host Disease market trends in the 7MM which include the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. The GvHD market forecast anticipates a CAGR of 8.2% through 2034 over the study period (2020-2034) from USD 1.3 Billion in 2023.

Regionally, the United States represents around 70% of the GvHD market, thanks to favorable reimbursement policies and rapid adoption of new, premium-priced therapies. The EU4 and the UK together account for about 19% of the GvHD market.

Download the GvHD market report to understand which factors are driving the Graft Versus Host Disease therapeutic market @ Graft Versus Host Disease Market Trends

The report also analyzes historical and projected epidemiology segmented by total allogenic transplant cases, total Graft Versus Host Disease prevalence, type-specific cases of Graft Versus Host Disease, Graft Versus Host Disease cases by grading, Graft Versus Host Disease cases by organ involvement, Graft Versus Host Disease cases by grading, Graft Versus Host Disease cases by organ involvement, total treated cases of Graft Versus Host Disease, and mortality adjusted treated cases of Graft Versus Host Disease.

DelveInsight estimates approximately 52K cases of Graft Versus Host Disease in the 7MM. In 2023, the EU4 and the UK recorded the highest incidence of Grade D[IV] Graft-Versus-Host Disease, aligning with patterns observed in hematologic malignancy transplants.

Discover evolving trends in Graft Versus Host Disease patient pool forecasts @ Graft Versus Host Disease Epidemiology Analysis.

The Graft Versus Host Disease Treatment Market Report provides insights into current GvHD treatment practices, emerging drugs, market share of individual therapies, and forecasts for the 7MM GvHD market size from 2020 to 2034. Current Graft Versus Host Disease therapies include steroids, NIKTIMVO, JAKAFI, IMBRUVICA, RYONCIL/TEMCELL HS, and ORENCIA, among others.

Graft Versus Host Disease Treatment is evolving from broad immunosuppression to targeted and cell-based therapies. JAKAFI (ruxolitinib), a JAK1/JAK2 inhibitor, is a cornerstone of GvHD treatment and generates substantial revenue due to its proven efficacy in steroid-refractory cases.

DelveInsight’s analysis indicates that the GvHD clinical trials market is highly active, with numerous investigational therapies in various stages of development. Notable candidates include ZEMAIRA (CSL Behring), EQ001 (Equillium/Biocon), MaaT013 (MaaT Pharma), RGI-2001 (REGiMMUNE), MC0518 (Medac), RLS-0071 (ReAlta Life Sciences), VIMSELTINIB (Deciphera Pharmaceuticals), ARSCIMED (Medsenic/BioSenic), ASC-930 (ASC Therapeutics), CYP-001 (Cynata Therapeutics), F-652 (Yifan Pharmaceutical), and APRAGLUTIDE (Ironwood), among others.

Unlock which Graft Versus Host emerging Disease drug is expected to capture the largest market share in 7MM by 2034. Visit the Graft Versus Host Disease Market Insights.

In January 2025, the FDA approved Incyte’s and Syndax’s Niktimvo (axatilimab-csfr) in 9 mg and 22 mg vial sizes for the treatment of chronic graft-versus-host disease (GVHD) in adults and pediatric patients based on data from the AGAVE-201 trial. This demonstrates encouraging progress in the graft versus host disease clinical trials market.

Upcoming milestones may include potential label expansions of cellular therapies like mesenchymal stromal cells, which could redefine first-line treatment strategies. However, challenges remain, such as standardizing response criteria across clinical trials and addressing the financial strain associated with chronic graft versus host disease treatment. DelveInsight’s report emphasizes that overcoming these challenges will require collaboration among pharmaceutical stakeholders and transplant networks to optimize patient stratification and track outcomes effectively.

Table of Contents

Related Reports

Graft versus host disease (GvHD) Pipeline Insight

Graft versus host disease Pipeline Insight provides comprehensive insights about the GvHD pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the GvHD companies, including Abbisko Therapeutics, Equillium, Theriva Biologics, Seres Therapeutics, CytoMed Therapeutics, Beijing Tide Pharmaceutical Co., Ltd, CTI BioPharma, ViGenCell Inc., Lipella Pharmaceuticals, Cellestia Biotech, Seres Therapeutics, Jiangsu HengRui Medicine Therapeutics, Genentech, AltruBio, Orca Bio, GSK and Amgen among others.

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Graft Versus Host Disease Market is Projected for Substantial Expansion from USD 1.3 Billion in 2023| DelveInsight

DelveInsight’s “Dystrophic Epidermolysis Bullosa Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Dystrophic Epidermolysis Bullosa, historical and forecasted epidemiology as well as the Dystrophic Epidermolysis Bullosa market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Dystrophic Epidermolysis Bullosa market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Dystrophic Epidermolysis Bullosa Market Forecast

Some of the key facts of the Dystrophic Epidermolysis Bullosa Market Report:

• The Dystrophic Epidermolysis Bullosa market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

• In February 2025, Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) has finalized a royalty financing agreement with Castle Creek Biosciences, Inc. to fund the Phase 3 clinical trial of D-Fi (FCX-007), the company’s lead candidate for treating dystrophic epidermolysis bullosa (DEB).

• In November 2024, Abeona Therapeutics Inc. (Nasdaq: ABEO) announced that the U.S. Food and Drug Administration (FDA) has accepted the resubmitted Biologics License Application (BLA) for prademagene zamikeracel (pz-cel), an investigational autologous cell-based gene therapy being evaluated as a potential treatment for recessive dystrophic epidermolysis bullosa (RDEB).

• The total market size for Dystrophic Epidermolysis Bullosa in the 7MM was approximately USD 550 million in 2023, and it is anticipated to grow during the forecast period.

• In 2023, the United States held the largest market size among the 7MM, totaling approximately USD 400 million.

• Among the EU4 and the UK, the UK represented the largest market size for Dystrophic Epidermolysis Bullosa, amounting to approximately USD 50 million.

• Spain recorded the smallest market size for Dystrophic Epidermolysis Bullosa among the 7MM, totaling approximately USD 20 million.

• In the 7MM, the total number of diagnosed prevalent cases of Dystrophic Epidermolysis Bullosa in 2023 was around 6,500, with the highest number reported in the US at approximately 3,500 cases, representing about 50% of the total.

• The United States had the highest total number of prevalent cases of Dystrophic Epidermolysis Bullosa in the 7MM, totaling 3,500 cases.

• In 2023, the age group most affected by Dystrophic Epidermolysis Bullosa included individuals aged 1 to 9 years, with approximately 1,300 cases reported.

• Key Dystrophic Epidermolysis Bullosa Companies: Krystal Biotech, Chiesi, Phoenicis Therapeutics, Aegle Therapeutics, Anterogen Co., Ltd., Abeona Therapeutics, Inc, Castle Creek Bioscience, Phoenix Tissue Repair, Inc., Scioderm, Inc., InMed Pharmaceuticals Inc., and others

• Key Dystrophic Epidermolysis Bullosa Therapies: VYJUVEK (beremagene geperpavec), FILSUVEZ (birch triterpenes), PTW-002 10 mg/g gel, AGLE 102, ALLO-ASC-SHEET, EB-101, FCX-007, PTR-01, SD-101-6.0 cream, INM-755 (cannabinol) cream, and others

• The Dystrophic Epidermolysis Bullosa epidemiology based on type-specific cases analyzed that the number of cases of dominant dystrophic epidermolysis bullosa is slight higher than recessive dystrophic epidermolysis bullosa

• The Dystrophic Epidermolysis Bullosa market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Dystrophic Epidermolysis Bullosa pipeline products will significantly revolutionize the Dystrophic Epidermolysis Bullosa market dynamics.

Dystrophic Epidermolysis Bullosa Overview

Dystrophic Epidermolysis Bullosa (DEB) is a rare genetic skin disorder characterized by fragile skin that is prone to blistering and wounding, often in response to minor friction or trauma. It results from mutations in the collagen genes, specifically COL7A1, leading to a deficiency or dysfunction of type VII collagen, which is essential for anchoring the layers of skin together. DEB can vary in severity, with symptoms ranging from mild skin fragility to severe complications, including scarring, deformities, and an increased risk of skin infections and skin cancer. Management focuses on wound care, pain relief, and preventing complications, as there is currently no cure for the condition.

Get a Free sample for the Dystrophic Epidermolysis Bullosa Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/dystrophic-epidermolysis-bullosa-market

Dystrophic Epidermolysis Bullosa Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Dystrophic Epidermolysis Bullosa Epidemiology Segmentation:

The Dystrophic Epidermolysis Bullosa market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Dystrophic Epidermolysis Bullosa

• Prevalent Cases of Dystrophic Epidermolysis Bullosa by severity

• Gender-specific Prevalence of Dystrophic Epidermolysis Bullosa

• Diagnosed Cases of Episodic and Chronic Dystrophic Epidermolysis Bullosa

Download the report to understand which factors are driving Dystrophic Epidermolysis Bullosa epidemiology trends @ Dystrophic Epidermolysis Bullosa Epidemiology Forecast

Dystrophic Epidermolysis Bullosa Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Dystrophic Epidermolysis Bullosa market or expected to get launched during the study period. The analysis covers Dystrophic Epidermolysis Bullosa market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Dystrophic Epidermolysis Bullosa Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Dystrophic Epidermolysis Bullosa Therapies and Key Companies

• VYJUVEK (beremagene geperpavec): Krystal Biotech

• FILSUVEZ (birch triterpenes): Chiesi

• PTW-002 10 mg/g gel: Phoenicis Therapeutics

• AGLE 102: Aegle Therapeutics

• ALLO-ASC-SHEET: Anterogen Co., Ltd.

• EB-101: Abeona Therapeutics, Inc

• FCX-007: Castle Creek Bioscience

• PTR-01: Phoenix Tissue Repair, Inc.

• SD-101-6.0 cream: Scioderm, Inc.

• INM-755 (cannabinol) cream: InMed Pharmaceuticals Inc.

Discover more about therapies set to grab major Dystrophic Epidermolysis Bullosa market share @ Dystrophic Epidermolysis Bullosa Treatment Landscape

Dystrophic Epidermolysis Bullosa Market Strengths

• A rising number of clinical trials are underway to assess innovative treatment approaches that have the potential to alter the progression of dystrophic epidermolysis bullosa and relieve its symptoms.

• Gene therapies for dystrophic epidermolysis bullosa are becoming a reality with the approval of VYJUVEK, the first FDA-approved topical gene therapy

Dystrophic Epidermolysis Bullosa Market Opportunities

• Currently, the lack of a cure and approved treatment presents a significant commercial opportunity for companies active in developing regenerative medicines, that is, cell and gene therapies.

• Significant advancements have been achieved in comprehending the molecular genetics and underlying mechanisms of dystrophic epidermolysis bullosa, laying the groundwork for developing potential treatments.

Scope of the Dystrophic Epidermolysis Bullosa Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Dystrophic Epidermolysis Bullosa Companies: Krystal Biotech, Chiesi, Phoenicis Therapeutics, Aegle Therapeutics, Anterogen Co., Ltd., Abeona Therapeutics, Inc, Castle Creek Bioscience, Phoenix Tissue Repair, Inc., Scioderm, Inc., InMed Pharmaceuticals Inc., and others

• Key Dystrophic Epidermolysis Bullosa Therapies: VYJUVEK (beremagene geperpavec), FILSUVEZ (birch triterpenes), PTW-002 10 mg/g gel, AGLE 102, ALLO-ASC-SHEET, EB-101, FCX-007, PTR-01, SD-101-6.0 cream, INM-755 (cannabinol) cream, and others

• Dystrophic Epidermolysis Bullosa Therapeutic Assessment: Dystrophic Epidermolysis Bullosa current marketed and Dystrophic Epidermolysis Bullosa emerging therapies

• Dystrophic Epidermolysis Bullosa Market Dynamics: Dystrophic Epidermolysis Bullosa market drivers and Dystrophic Epidermolysis Bullosa market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Dystrophic Epidermolysis Bullosa Unmet Needs, KOL’s views, Analyst’s views, Dystrophic Epidermolysis Bullosa Market Access and Reimbursement

To know more about Dystrophic Epidermolysis Bullosa companies working in the treatment market, visit @ Dystrophic Epidermolysis Bullosa Clinical Trials and Therapeutic Assessment

Table of Contents

1. Dystrophic Epidermolysis Bullosa Market Report Introduction

2. Executive Summary for Dystrophic Epidermolysis Bullosa

3. SWOT analysis of Dystrophic Epidermolysis Bullosa

4. Dystrophic Epidermolysis Bullosa Patient Share (%) Overview at a Glance

5. Dystrophic Epidermolysis Bullosa Market Overview at a Glance

6. Dystrophic Epidermolysis Bullosa Disease Background and Overview

7. Dystrophic Epidermolysis Bullosa Epidemiology and Patient Population

8. Country-Specific Patient Population of Dystrophic Epidermolysis Bullosa

9. Dystrophic Epidermolysis Bullosa Current Treatment and Medical Practices

10. Dystrophic Epidermolysis Bullosa Unmet Needs

11. Dystrophic Epidermolysis Bullosa Emerging Therapies

12. Dystrophic Epidermolysis Bullosa Market Outlook

13. Country-Wise Dystrophic Epidermolysis Bullosa Market Analysis (2020–2034)

14. Dystrophic Epidermolysis Bullosa Market Access and Reimbursement of Therapies

15. Dystrophic Epidermolysis Bullosa Market Drivers

16. Dystrophic Epidermolysis Bullosa Market Barriers

17. Dystrophic Epidermolysis Bullosa Appendix

18. Dystrophic Epidermolysis Bullosa Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Dystrophic Epidermolysis Bullosa Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Krystal Biotech, Chiesi, Phoenicis Therapeutics, Aegle Therapeutics, Anterogen

The 7MM Polycythemia Vera market size reached ~USD 1,900 million in 2024 and is projected to grow significantly through 2034. Key players such as Incyte/Novartis, PharmaEssentia/AOP Orphan Pharmaceuticals, Protagonist Therapeutics, Merck (Imago BioSciences), Italfarmaco, Ionis Pharmaceutical, Silence Therapeutics, Perseus Proteomics, AbbVie, Johnson & Johnson Innovative Medicine, Mabwell (Shanghai) Bioscience and Disc Medicine, GluBio Therapeutics, and others are spearheading innovations in treatment approaches, addressing critical unmet needs in managing this chronic myeloproliferative neoplasm.

DelveInsight’s report, titled “Polycythemia Vera Market Insight, Epidemiology and Market Forecast -2034”, provides a detailed assessment of historical and projected market trends from 2020 to 2034. The analysis encompasses epidemiology segmentation, treatment paradigms, emerging therapies, and competitive dynamics, offering stakeholders actionable insights into market opportunities and challenges. The report highlights how the anticipated introduction of targeted therapies and improved diagnostic tools will reshape the PV treatment landscape over the next decade.

In 2024, the United States dominated the Polycythemia market, accounting for over 75% of the total market size, which amounts to USD 1.9 Billion across the 7MM. Among EU4 countries, Germany accounts for the maximum market size, while the United Kingdom occupies the bottom of the ladder in 2024. This trend is expected to continue reflecting disparities in treatment accessibility, Polycythemia Vera prevalence, and diagnostic rates across regions.

Download the report to understand which factors are driving the Polycythemia Vera therapeutic market @ Polycythemia Vera Market Trends

The report also provides historical as well as forecasted PV epidemiology segmented by Total Prevalent Population of Polycythemia Vera, Prevalent Population of Polycythemia Vera Based on Symptoms, Gender-specific Prevalence of Polycythemia Vera, Prevalence of Polycythemia Vera by Gene Mutation, Prevalence of Polycythemia Vera Based on Risk, and Age-specific Prevalence of Polycythemia Vera in the 7MM.

The report estimates that the 7MM had approximately 320,000 Polycythemia Vera cases in 2024, with numbers expected to rise steadily during the forecast period. Gender-specific data indicates that approximately 56% of the patient share in 7MM is attributed to males, whereas 44% are females. Additionally, across all races and ethnicities, the PV incidence is about 2.8 per 100,000 men and roughly 1.3 per 100,000 women.

Discover evolving trends in Polycythemia Vera patient pool forecasts @ Polycythemia Vera Epidemiology Analysis.

Polycythemia Vera management currently relies on a combination of treatments, including phlebotomy, cytoreductive agents such as hydroxyurea, and JAK inhibitors like JAKAFI (RUXOLITINIB) from Incyte/Novartis. Other notable medications used in the management of PV include BESREMi (PharmaEssentia/AOP Orphan Pharmaceuticals) and PEGASYS (pharmaand GmbH). Given its very different MoA compared to JAKAFI and BESREMi, rusfertide could become a viable alternative as an earlier line of therapy. In 2024, JAKAFI generated the highest revenue among these Polycythemia Vera therapies.

While these therapies help manage symptoms and reduce thrombotic risks, they are associated with limitations including drug resistance, long-term toxicity, and inadequate control of disease progression. DelveInsight’s report emphasizes that a significant number of patients experience suboptimal responses to existing treatments, highlighting a pressing need for novel mechanisms of action.

The report highlights that the Polycythemia Vera pipeline features several investigational therapies across phases of development. Notable candidates include DIVESIRAN (Silence Therapeutics), PPMX-T003 (Perseus Proteomics), NAVITOCLAX (AbbVie), VAC85135 (Johnson & Johnson), 9MW3011/DISC-3405 (Mabwell), GLB-001 (GluBio Therapeutic) and others.

Unlock which emerging Polycythemia Vera drug is expected to capture the largest market share in 7MM by 2034. Visit the Polycythemia Vera Market Insights.

In the latest financial statement, Incyte reported strong growth for Jakafi with net revenues of $773 million in Q4 2024 and $2.79 billion for the full year. In March 2025, Protagonist Therapeutics and Takeda announced positive topline results from the Phase 3 VERIFY study, where rusfertide met its primary and all secondary endpoints in treating polycythemia vera. These recent developments indicate positive momentum in the Polycythemia Vera treatment market.

Despite progress, challenges such as delayed diagnosis, treatment-related anemia, and lack of consensus on optimal monitoring strategies persist. DelveInsight’s analysis identifies biomarker development and patient-centric drug delivery systems as key areas for innovation.

Table of Contents

Related Reports

Polycythemia Vera Pipeline Insight

Polycythemia Vera Pipeline Insight provides comprehensive insights about the Polycythemia Vera pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Polycythemia Vera companies, including Silence Therapeutics, Ionis Pharmaceuticals, Perseus Proteomics, Kartos Therapeutics, and Disc Medicine among others.

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Polycythemia Vera Market Set for Significant Growth Across 7MM Driven by Innovative Therapies and Rising Prevalence | DelveInsight